The IPO window may have cracked open, but it seems some former startups have no intention of going public. Makes sense, in a way: IPOs were traditionally a way to raise money, and if you can manage to ...
Databricks is raising over $4 billion in Series L funding that would value the data-analytics and artificial-intelligence software company at $134 billion, an increase of 34% from its last funding ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback